「eGFR」の共起表現一覧(1語右で並び替え)
該当件数 : 29件
already bound an agonist (e.g., in the case of | EGFR), allowing this agonist to go and stimulate a r |
s the formation and activation of ErbB1/ErbB-2 ( | EGFR and HER2) heterodimers that have a prominent ro |
investigated for breast cancer as well as other | EGFR and Her2 driven cancers. |
1 cell proliferation, due to down-regulation of | EGFR and inhibition of AKT and MAPK phosphorylation. |
ed that even though matuzumab efficiently binds | EGFR and blocks its phosphorylation, it is not as ef |
losely related protein tyrosine kinases such as | EGFR and its close relative HER2. |
discriminate between the kinase domains of the | EGFR and that of the insulin receptor. |
ATP-competitive, although they are when used in | EGFR as described in QSAR studies. |
Mutations involving | EGFR could lead to its constant activation which cou |
In 2005 it was shown that inhibitors of | EGFR could enhance axonal regeneration on non-conduc |
each antibody may elicit different responses on | EGFR downstream signalling pathways with a distinct |
member of the epidermal growth factor receptor ( | EGFR) family of receptor tyrosine kinases. |
ein family or epidermal growth factor receptor ( | EGFR) family is a family of four structurally relate |
Consequently, mutations of | EGFR have been identified in several types of cancer |
Thus gefitinib is an | EGFR inhibitor. |
al to be transmitted even in the presence of an | EGFR inhibitor. |
The target protein ( | EGFR) is also sometimes referred to as Her1 or ErbB- |
2 (Her2) and epidermal growth factor receptor ( | EGFR) kinases. |
2 (Her2) and epidermal growth factor receptor ( | EGFR) kinases. |
r for IRESSA than chemotherapy in patients with | EGFR mutation positive tumours (HR 0.48, 95 per cent |
Afatinib is not only active against | EGFR mutations targeted by first generation TKIs lik |
h affinity to epidermal growth factor receptor ( | EGFR) on the cell surface and stimulating the intrin |
g a mutated IGF-1 receptor to act as one of the | EGFR partners in the homodimer, so forming a heterod |
ssociated with epidermal growth factor receptor | EGFR), RNA stabilization products with its Armored R |
tion as well as cytoskeletal reorganization and | EGFR signaling. |
lood clotting protein fibrinogen also activates | EGFR, thereby inhibiting regeneration of axons. |
the Syp/PTP1D protein, Grb2 binds to activated | EGFR through Shc, another adaptor protein that forms |
nhibitor of epidermal growth factor receptor's ( | EGFR) tyrosine kinase domain. |
binds to the epidermal growth factor receptor ( | EGFR) with high affinity. |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると
|
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると
|